Agilon Health Inc. (AGL) Reports In-Line Q2 EPS; lowers guidance

Agilon Health Inc. (NYSE: AGL) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.56 billion.

GUIDANCE:

Agilon Health Inc. sees Q3 2024 revenue of $1.465-1.475 billion, versus the consensus of $1.541 billion.

Agilon Health Inc. sees FY2024 revenue of $6.01-6.04 billion, versus the consensus of $6.164 billion.

For earnings history and earnings-related data on Agilon Health Inc. (AGL) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield
• AeroVironment restates quarterly financials, citing $89M goodwill error